摘要
目的研究乙肝肝硬化患者治疗上运用恩替卡韦的治疗效果。方法简单随机选取该院于2019年1月—2020年2月收治的80例乙肝肝硬化患者为研究对象,按照随机数表法分为对照组和观察组,每组40例。对照组用阿德福韦酯治疗,观察组用恩替卡韦治疗,对比两组总体治疗效果。结果观察组为95.0%,对照组为80.0%,观察组的治疗总有效率更高,差异有统计学意义(χ^(2)=4.114,P<0.05);治疗后两组患者的谷丙转氨酶、总胆红素水平均显著低于治疗前,观察组低于对照组,治疗后两组的白蛋白水平均显著高于治疗前,观察组高于对照组,差异有统计学意义(P<0.05);两组患者治疗后的透明质酸、C型胶原、层粘连蛋白水平均显著低于治疗前,且观察组的各项肝纤维指标显著低于对照组,差异有统计学意义(P<0.05);观察组患者在治疗期间的不良反应发生率显著低于对照组,差异有统计学意义(χ^(2)=6.275,P<0.05)。结论用恩替卡韦治疗乙肝肝硬化兼具有效性和安全性,同时有利于改善患者的肝功能,有效阻止患者病情的进一步发展,治疗优势突出,故具备临床应用和推广价值。
Objective To study the therapeutic effect of entecavir in the treatment of patients with hepatitis B and liver cirrhosis.Methods The 80 patients with hepatitis B cirrhosis admitted to the hospital from January 2019 to February 2020 were simple randomly selected as the research objects,and were divided into a control group and an observation group according to a random number table method,with 40 cases in each group.The control group was treated with adefovir dipivoxil,and the observation group was treated with entecavir.The overall treatment effects of the two groups were compared.Results The observation group was 95.0%,and the control group was 80.0%.The observation group has a higher total effective rate of treatment,and the difference was statistically significant(χ^(2)=4.114,P<0.05).After treatment,the levels of alanine aminotransferase and total bilirubin of the two groups of patients were significantly lower than before treatment,and the observation group was lower than the control group.After treatment,the albumin levels of the two groups were significantly higher than before treatment,and the observation group was higher than the control group.The difference was statistically significant(P<0.05).After treatment,the levels of hyaluronic acid,type C collagen,and laminin in the two groups were significantly lower than before treatment,and the liver fiber indexes of the observation group were significantly lower than those of the control group,the difference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group during the treatment period was significantly lower than that in the control group,and the difference was statistically significant(χ^(2)=6.275,P<0.05).Conclusion Entecavir treatment of hepatitis B cirrhosis is both effective and safe, and at the same time beneficial to improve the liver function of the patient, effectively prevent the further development of the patient's condition, and has outstanding therapeutic advantages, so it has clinical application and promotion value.
作者
孔德钱
李昌
王琳
KONG Deqian;LI Chang;WANG Lin(Yangchun People's Hospital,the Second Department of Internal Medicine,Yangchun,Guangdong Province,529600 China)
出处
《中外医疗》
2021年第12期79-82,共4页
China & Foreign Medical Treatment
关键词
乙肝肝硬化
恩替卡韦
临床疗效
Hepatitis B cirrhosis
Entecavir
Clinical efficacy
